Literature DB >> 20713658

Frequency of spontaneous resistance to fosfomycin combined with different antibiotics in Pseudomonas aeruginosa.

Alexandro Rodríguez-Rojas, Alejandro Couce, Jesús Blázquez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20713658      PMCID： PMC2976149          DOI： 10.1128/AAC.00415-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  14 in total

1.  In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa.

Authors:  Pornpimol Pruekprasert; Wanutsanun Tunyapanit
Journal:  Southeast Asian J Trop Med Public Health       Date:  2005-09       Impact factor: 0.267

2.  Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis.

Authors:  S Faruqi; J McCreanor; T Moon; R Meigh; A H Morice
Journal:  Int J Antimicrob Agents       Date:  2008-08-13       Impact factor: 5.283

Review 3.  Potential of old-generation antibiotics to address current need for new antibiotics.

Authors:  Matthew E Falagas; Alexandros P Grammatikos; Argyris Michalopoulos
Journal:  Expert Rev Anti Infect Ther       Date:  2008-10       Impact factor: 5.091

4.  Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?

Authors:  David M Livermore
Journal:  Clin Infect Dis       Date:  2002-01-25       Impact factor: 9.079

5.  Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections.

Authors:  María D Maciá; David Blanquer; Bernat Togores; Jaume Sauleda; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

Review 6.  Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.

Authors:  B Tümmler; J Bosshammer; S Breitenstein; I Brockhausen; P Gudowius; C Herrmann; S Herrmann; T Heuer; P Kubesch; F Mekus; U Römling; K D Schmidt; C Spangenberg; S Walter
Journal:  Behring Inst Mitt       Date:  1997-02

7.  High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection.

Authors:  A Oliver; R Cantón; P Campo; F Baquero; J Blázquez
Journal:  Science       Date:  2000-05-19       Impact factor: 47.728

8.  Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa.

Authors:  Sakuo Yamada; Yukiyoshi Hyo; Sachiyo Ohmori; Masanobu Ohuchi
Journal:  Chemotherapy       Date:  2007-03-15       Impact factor: 2.544

9.  Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model.

Authors:  Takeshi Mikuniya; Yoshihisa Kato; Takashi Ida; Kazunori Maebashi; Koichi Monden; Reiko Kariyama; Hiromi Kumon
Journal:  J Infect Chemother       Date:  2007-10-30       Impact factor: 2.211

10.  An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants.

Authors:  Nicole T Liberati; Jonathan M Urbach; Sachiko Miyata; Daniel G Lee; Eliana Drenkard; Gang Wu; Jacinto Villanueva; Tao Wei; Frederick M Ausubel
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205
View more
  9 in total

1.  Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics.

Authors:  A Bruce Montgomery; Paul R Rhomberg; Tammy Abuan; Kathie-Anne Walters; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

2.  Bypass of genetic constraints during mutator evolution to antibiotic resistance.

Authors:  Alejandro Couce; Alexandro Rodríguez-Rojas; Jesús Blázquez
Journal:  Proc Biol Sci       Date:  2015-04-07       Impact factor: 5.349

3.  Antimicrobial Activity of Fosfomycin-Tobramycin Combination against Pseudomonas aeruginosa Isolates Assessed by Time-Kill Assays and Mutant Prevention Concentrations.

Authors:  María Díez-Aguilar; María Isabel Morosini; Ana P Tedim; Irene Rodríguez; Zerrin Aktaş; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

Review 4.  Pseudomonas aeruginosa polymicrobial interactions during lung infection.

Authors:  Karishma Bisht; Jiwasmika Baishya; Catherine A Wakeman
Journal:  Curr Opin Microbiol       Date:  2020-02-12       Impact factor: 7.934

5.  Cationic Peptides Facilitate Iron-induced Mutagenesis in Bacteria.

Authors:  Alexandro Rodríguez-Rojas; Olga Makarova; Uta Müller; Jens Rolff
Journal:  PLoS Genet       Date:  2015-10-02       Impact factor: 5.917

6.  "Stormy waters ahead": global emergence of carbapenemases.

Authors:  Gopi Patel; Robert A Bonomo
Journal:  Front Microbiol       Date:  2013-03-14       Impact factor: 5.640

7.  Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions.

Authors:  Gerard McCaughey; Paul Diamond; J Stuart Elborn; Matt McKevitt; Michael M Tunney
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

Review 8.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553

9.  Convergent phenotypic evolution towards fosfomycin collateral sensitivity of Pseudomonas aeruginosa antibiotic-resistant mutants.

Authors:  Pablo Laborda; José L Martínez; Sara Hernando-Amado
Journal:  Microb Biotechnol       Date:  2021-05-07       Impact factor: 5.813
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.